Thymopentin (TP-5) in the treatment of rheumatoid arthritis.

Abstract

A randomized control trial of TP-5 in rheumatoid arthritis is reported. In a multicentre study, 76 patients were treated with TP-5 50 mg or placebo three times a week for 3 weeks as a slow intravenous injection, and followed for 7 weeks. Clinical parameters such as the Ritchie index and sum score of swollen joints improved significantly on TP-5 compared to placebo. Laboratory parameters did not change but an increased skin test score to common recall antigens was observed. Toxicity was minimal. TP-5 is a potentially useful agent in the treatment of rheumatoid arthritis, although further studies are required to determine the optimal treatment regimen.

• Authors: B K Kantharia, N J Goulding, N D Hall, J Davies, P J Maddison, P A Bacon, M Farr, J A Wojtulewski, K M Englehart, S P Liyanage
• Journal: British journal of rheumatology (Br J Rheumatol) Vol. 28 Issue 2 Pg. 118-23 (Apr 1989) ISSN: 0263-7103 [Print] England
• PMID: 2650797 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Peptide Fragments
• Thymopoietins
• Thymus Hormones
• Thymopentin

Topics

• Arthritis, Rheumatoid (blood, drug therapy, physiopathology)
• Clinical Trials as Topic
• Humans
• Hypersensitivity, Delayed (immunology)
• Peptide Fragments (adverse effects, therapeutic use)
• Severity of Illness Index
• Skin Tests
• T-Lymphocytes (classification)
• Thymopentin
• Thymopoietins (adverse effects, therapeutic use)
• Thymus Hormones (therapeutic use)